KITENIN-CCL20 axis is a potential therapeutic target for modulating immunosuppressive tumor microenvironment in glioblastoma
- Neurotherapeutics. 2026 Jan;23(1):e00853. doi: 10.1016/j.neurot.2026.e00853.
- 1. Department of Neurosurgery, Chonnam National University Hwasun Hospital and Medical School, Hwasun, South Korea; Department of Pathology, Chonnam National University Hwasun Hospital and Medical School, Hwasun, South Korea.
- 2. Department of Pathology, Chonnam National University Hwasun Hospital and Medical School, Hwasun, South Korea.
- 3. Department of Neurosurgery, Chonnam National University Hwasun Hospital and Medical School, Hwasun, South Korea.
- 4. Department of Rehabilitation, Chonnam National University Hwasun Hospital and Medical School, Hwasun, South Korea.
- 5. Department of Radiology, Chonnam National University Hwasun Hospital and Medical School, Hwasun, South Korea.
- 6. Department of Microbiology and Immunology, Chonnam National University Medical School, Hwasun, South Korea; BioMedical Sciences Graduate Program (BMSGP), Chonnam National University, Hwasun, South Korea.
- 7. Medical Research Center (MRC) for Immunotherapy of Cancer, Chonnam National University Medical School, Hwasun, South Korea.
- 8. Department of Pharmacology, Chonnam National University Medical School, Hwasun, South Korea.
- 9. Department of Pathology, Chonnam National University Hwasun Hospital and Medical School, Hwasun, South Korea; BioMedical Sciences Graduate Program (BMSGP), Chonnam National University, Hwasun, South Korea. Electronic address: [email protected].
- 10. Department of Neurosurgery, Chonnam National University Hwasun Hospital and Medical School, Hwasun, South Korea. Electronic address: [email protected].
Glioblastoma (GBM) is characterized by an immunosuppressive tumor microenvironment (TME), limiting the effectiveness of existing treatments. We investigated the role of KAI1 COOH-terminal interacting tetraspanin (KITENIN), a metastasis-promoting protein, in mediating this immunosuppression, focusing on its effect on cytokine secretion and tumor-infiltrating lymphocyte (TIL) profiles in the TME. Employing cytokine array and Luminex multiplex assays, we found increased level of CC chemokine ligand 20 (CCL20) within KITENIN-overexpressed (KIT-HA) GL261 cell supernatants. Immunohistochemical analyses using GBM samples confirmed that both KITENIN and CCL20 expressions co-directionally increased, and this was associated with decreased survival by TCGA analysis. Myeloid-derived suppressor cells (MDSCs), macrophages, and regulatory T cells were increased in brain tumors implanted with KIT-HA GL261. In contrast, functional cytotoxic T cells were decreased in the KIT-HA group. Furthermore, compared with control conditioned medium, KIT-HA GL261 conditioned medium expanded CD45+CD11b+Ly6G-Ly6Chigh monocytic MDSCs (M-MDSCs), an effect that was abrogated by CCL20 downregulation. In vivo neutralization of CCL20 resulted in reduced tumor volume, prolonged survival, and decreased M-MDSCs, thus affirming the role of CCL20 in mediating immunosuppression. Our findings underscore the KITENIN-CCL20 axis as a promising target for alleviating the immunosuppressive TME in GBM, potentially unlocking new avenues for GBM immunotherapy.
-
Cat. No.Product NameDescriptionTargetResearch Area
-